Table 3.

Confirmed or unconfirmed best responses to ixazomib by investigator assessment

Response	Dose-escalation cohorts (n = 23)	Expansion cohorts (n = 30*)	Total (N = 50)
Best response, n (%)
CR	0	0	0
PR	2 (9)	8 (27)†	9 (18)†
VGPR	1 (4)	0	1 (2)
MR	0	1 (3)	1 (2)
SD	7 (30)	9 (30)	15 (30)
PD	14 (61)	12 (40)	25 (50)
Response rates, n (%) (95% CI)
CR+VGPR	1 (4) (<1, 22)	0	1 (2) (<1, 11)
≥PR	2 (9) (1, 28)	8 (27) (12, 46)	9 (18) (9, 31)
≥MR	2 (9) (1, 28)	9 (30) (15, 49)	10 (20) (10, 34)

CR, complete response; PD, progressive disease; VPGR, very good partial response.

^*Includes 3 patients from the MTD dose-escalation cohort.

^†2 PRs unconfirmed; 1 PR unconfirmed but confirmed as MR. Responses were seen across the expansion cohorts, including 2, 3, 1, and 2 PRs in the relapsed and refractory, bortezomib-relapsed, PI-naive, and prior carfilzomib cohorts, respectively.